Champions Oncology, Inc.
CSBR · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Revenue | $56,944 | $50,155 | $53,870 | $49,109 |
| % Growth | 13.5% | -6.9% | 9.7% | – |
| Cost of Goods Sold | $30,029 | $29,401 | $29,532 | $23,632 |
| Gross Profit | $26,915 | $20,754 | $24,338 | $25,477 |
| % Margin | 47.3% | 41.4% | 45.2% | 51.9% |
| R&D Expenses | $6,825 | $9,544 | $11,545 | $9,374 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $15,244 | $18,131 | $17,242 | $15,496 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $22,069 | $27,675 | $28,787 | $24,870 |
| Operating Income | $4,846 | -$6,921 | -$4,449 | $607 |
| % Margin | 8.5% | -13.8% | -8.3% | 1.2% |
| Other Income/Exp. Net | -$220 | -$387 | -$818 | -$24 |
| Pre-Tax Income | $4,626 | -$7,308 | -$5,267 | $583 |
| Tax Expense | -$75 | -$32 | $68 | $35 |
| Net Income | $4,701 | -$7,276 | -$5,335 | $548 |
| % Margin | 8.3% | -14.5% | -9.9% | 1.1% |
| EPS | 0.34 | -0.54 | -0.39 | 0.042 |
| % Growth | 163% | -38.5% | -1,039.8% | – |
| EPS Diluted | 0.33 | -0.54 | -0.39 | 0.039 |
| Weighted Avg Shares Out | 13,660 | 13,548 | 13,542 | 13,197 |
| Weighted Avg Shares Out Dil | 14,267 | 13,548 | 13,542 | 14,160 |
| Supplemental Information | – | – | – | – |
| Interest Income | $87 | $92 | $0 | $0 |
| Interest Expense | $27 | $28 | $0 | $24 |
| Depreciation & Amortization | $1,640 | $1,867 | $3,198 | $2,413 |
| EBITDA | $6,293 | -$5,413 | -$2,069 | $2,996 |
| % Margin | 11.1% | -10.8% | -3.8% | 6.1% |